Tatva Chintan Pharma Chem Limited (TCPCL), an integrated niche speciality chemical company, Q3 FY23 revenue from operations was Rs. 90.1 crore, declined by 27% whereas net profit for the quarter was Rs. 7.1 crore, declined by 78%. 

Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%. 

Phase Transfer Catalysts (PTCs) comprised 41% of the revenue during H1 FY23, reporting a revenue growth of nearly 69% YoY basis. These products are used as catalysts in manufacturing Pharmaceutical APIs, Flavours & Fragrances, Agrochemicals, etc. 

Structure Directing Agents (SDAs) comprised 9% of the revenue during H1 FY23, reporting a decline of 88% YoY basis. SDAs are the key building blocks for manufacturing high precision zeolite which finds application in automotive emission control, petrochemicals, continuous flow chemistry, etc. 

Electrolyte Salts (ES) comprised 6% of the revenue and in absolute numbers revenue grew by 846% YoY. ES are used in super capacitor batteries which find application in automobile, electronics and energy storage devices. 

Pharma Agro Intermediates and Specialty Chemicals (PASC) product category comprising 43% of the revenue, saw a YoY growth of 45%. PASC finds application in Pharmaceutical APIs, Agro Actives, paints and coatings, Li battery, detergents, personal care products, etc. 

Commenting on Q2 FY23 Results, Chintan Shah, Managing Director, TCPCL said, "EBITDA during this quarter was Rs. 11.2 crore, a decline of 68% YoY and 27% QoQ. PAT was Rs 7.1 crore, a decline of 78% YoY and 27% QoQ. Compared on a QoQ basis, the profitability has dropped due to increase in costs such as power & fuel, packing and employee cost during this quarter."